Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Welgene Biotech CoROCO:6661 70 Days Payable is 37.11 as of Dec. 2025, which is 16% above its 10-year median of 31.94. GuruFocus rates ROCO:6661 with a GF Score™ of 70/100 and a GF Value™ of NT$29.93 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Welgene Biotech Co ranks worse than 77.37% on this metric.
The historical rank and industry rank for Welgene Biotech Co's Days Payable or its related term are showing as below:
ROCO:6661'
s Days Payable Range Over the Past 10 Years
Min: 26.82 Med: 31.94 Max: 41.26
Current: 33.02
During the past 12 years, Welgene Biotech Co's highest Days Payable was 41.26. The lowest was 26.82. And the median was 31.94.
ROCO:6661's Days Payable is ranked worse than 77.37% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs ROCO:6661: 33.02
Welgene Biotech Co's Days Payable
increased
from Dec. 2024 (24.34) to Dec. 2025 (37.11).
It may suggest that Welgene Biotech Codelayed paying its suppliers.
Welgene Biotech Co Days Payable Related Terms
Welgene Biotech Co Days Payable Historical Data
* Premium members only.
The historical data trend for Welgene Biotech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6661 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Welgene Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Welgene Biotech Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Welgene Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Welgene Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Welgene Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Welgene Biotech Co (ROCO:6661) has a Days Payable of 37.11 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Welgene Biotech Co and its competitors. This is 16% above median its historical median of 31.94. Over the past decade, Welgene Biotech Co's Days Payable has ranged from 26.82 to 41.26. According to the industry distribution chart, Welgene Biotech Co ranks #147 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 77.4%.
Is Welgene Biotech Co's Days Payable too high?
Welgene Biotech Co's current Days Payable of 37.11 is 16% above median its 10-year median of 31.94. Over the past 10 years, this metric has ranged from a low of 26.82 to a high of 41.26. The Medical Diagnostics & Research industry median Days Payable is 64.64. Welgene Biotech Co's value of 37.11 is 42.6% below this industry median. Based on the distribution chart, Welgene Biotech Co ranks #147 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Welgene Biotech Co has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Welgene Biotech Co's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Welgene Biotech Co ranks #147 out of 190 companies for Days Payable. This places Welgene Biotech Co in the lower half of its industry. The industry median Days Payable is 64.64. Welgene Biotech Co's value of 37.11 is 42.6% below this benchmark. Historically, Welgene Biotech Co's own Days Payable has ranged from 26.82 to 41.26 over the past decade. While the company's 10-year median is 31.94 vs. the industry median of 64.64, Welgene Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Welgene Biotech Co's current Days Payable of 37.11 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Welgene Biotech Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Welgene Biotech Co's current Days Payable is 37.11, which is 16% above median its own 10-year median of 31.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welgene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Welgene Biotech Co (ROCO:6661) is currently considered Possible Value Trap. The stock's GF Value™ is NT$29.93, compared to a current price of NT$17.55 — trading 41.4% below its estimated fair value. The current Days Payable is 37.11, which is 16% above median its 10-year median of 31.94 and 42.6% below the Medical Diagnostics & Research industry median of 64.64. Welgene Biotech Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Welgene Biotech Co (ROCO:6661), the current Days Payable is 37.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Welgene Biotech Co (ROCO:6661) Overvalued in 2026?
Based on GuruFocus' analysis, Welgene Biotech Co stock appears to be undervalued.
The current stock price of NT$17.55 is trading 41.4% below its estimated GF Value™ of NT$29.93.
GuruFocus considers Welgene Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:6661:
Days Payable: 37.11 (16% above median its 10-year median of 31.94)
GF Value™: NT$29.93 vs. price of NT$17.55 (41.4% below fair value)
Industry Position: 42.6% below the Medical Diagnostics & Research median (#147 of 190)
No single metric tells the full story. See the ROCO:6661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Welgene Biotech Co Ltd is engaged in providing genetic and biotechnology testing services and related products. Its offerings include next-generation sequencing (NGS) services, DNA microarray and PCR-based testing solutions, biotechnology reagents, diagnostic products, and laboratory instruments. The company also engages in the trading of medical and biotechnology equipment.
70GF Score
Get the complete analysis for ROCO:6661
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6661 has been successfully added to your 
